Lilly Completes Acquisition Of Sigilon Therapeutics
08/14/23, 11:29 AM
Location
indianapolis
Industry
pharmaceutical
manufacturing
health care
biotechnology
health care
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes.
Company Info
Location
Indianapolis, Indiana, United States
Company info
Lilly is a medicine company turning science into healing to make life better for people around the world. They have been pioneering life-changing discoveries for nearly 150 years, and today their medicines help more than 51 million people across the globe. Lilly is focused on redefining diabetes care, treating obesity, advancing the fight against Alzheimer's disease, providing solutions to immune system disorders, and transforming difficult-to-treat cancers into manageable diseases.